Epigenetic modulation of the tumor immune microenvironment by nanoinducers to potentiate cancer immunotherapy

References

1. 1.↵
   2. Lai P,
   3. Wang Y.

   Epigenetics of cutaneous T-cell lymphoma: biomarkers and therapeutic potentials. Cancer Biol Med. 2021;18:34–51.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   2. Jones PA,
   3. Ohtani H,
   4. Chakravarthy A,
   5. De Carvalho DD.

   Epigenetic therapy in immune-oncology. Nat Rev Cancer. 2019;19:151–61.

   OpenUrlCrossRefPubMed
3. 3.↵
   2. Sheng WQ,
   3. LaFleur MW,
   4. Nguyen TH,
   5. Chen SJ,
   6. Chakravarthy A,
   7. Conway JR, et al.

   LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade. Cell. 2018;174:549–63.

   OpenUrlPubMed
4. 4.↵
   2. Morel D,
   3. Jeffery D,
   4. Aspeslagh S,
   5. Almouzni G,
   6. Postel-Vinay S.

   Combining epigenetic drugs with other therapies for solid tumours – past lessons and future promise. Nat Rev Clin Oncol. 2020;17:91–107.

   OpenUrlPubMed
5. 5.↵
   2. Xue Y,
   3. Gao YT,
   4. Meng FL,
   5. Luo L.

   Recent progress of nanotechnology-based theranostic systems in cancer treatments. Cancer Biol Med. 2021;18:336–51.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   2. Zhai YH,
   3. Wang JM,
   4. Lang TQ,
   5. Kong Y,
   6. Rong R,
   7. Cai Y, et al.

   T lymphocyte membrane-decorated epigenetic nanoinducer of interferons for cancer immunotherapy. Nat Nanotechnol. 2021. doi:10.1038/s41565-021-00972-7.

   OpenUrlCrossRef